Skip to main content

Table 2 Cytokine data from patients with biliary obstruction (cancer and benign) in the combined training and test datasets

From: Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Analyte Median (95% CI) PDAC with biliary obstruction (n = 83) Median (95% CI) BBO plus CP with biliary obstruction (n = 27) P Value PDAC with biliary obstruction vs. Obstructed BBO plus CP with biliary obstruction Median (95% CI) PDAC without biliary obstruction (n = 44) P value PDAC with biliary obstruction vs. PDAC without biliary obstruction PDAC
CA19-9 0.16 -1.10 <0.05 -1.06 <0.05
(-0.6 to 0.4) (-2.3 to -0.5) (-1.8 to 0.1)
Eotaxin 0.48 0.40 NS 0.51 NS
(0.2 to 0.6) (-0.3 to 0.7) (0.2 to 0.8)
IL-1b 0.23 0.25 NS 0.24 NS
(0.1 to 0.4) (0.03 to 0.4) (0.002 to 0.4)
IL-1ra 0.72 0.33 NS 0.79 NS
(0.4 to 1.0) (-0.8 to 1.0) (0.2 to 1.3)
IL-6 1.38 1.97 NS 0.92 NS
(1.2 to 1.7) (1.0 to 2.4) (0.7 to 1.3)
IL-8 0.96 0.39 <0.05 0.89 NS
(0.8 to 1.4) (0.2 to 1.1) (0.5 to 1.2)
IP-10 -1.79 -2.59 <0.05 -2.06 NS
(-2.0 to -1.6) (-2.8 to -2.2) (-2.5 to -1.7)
MCP-1 0.26 0.56 NS 0.40 NS
(0.05 to 0.6) (0.001 to 1.4) (0.08 to 0.8)
MIP-1b 0.34 -0.06 <0.05 0.29 NS
(0.2 to 0.5) (-0.5 to 0.3) (-0.09 to 0.35)
PDGF 0.42 -0.27 <0.01 0.51 NS
(0.2 to 0.5) (-0.9 to 0.4) (0.1 to 0.7)
  1. Median normalised log2 transformed data are presented for each analyte; the 95% CI are given in brackets. PDAC = Cancer, CP = Chronic Pancreatitis, BBO = Benign Biliary Obstruction. Wilcoxon signed rank tests were used to generate p-values for group comparisons. NS - non-significant.